TP53 and cancer: Inscrutinizing 227 specimens from eight diverse sources, including 107 early-onset cases,their analysis identified seven putative driver genes for OTSCC, unveiling two hithertounreported genes-ATXN1 and CDC42EP1. Impressively,82.8% of specimens exhibited missense or truncating mutations in at least one of theseseven genes, with TP53 emerging as the most frequently mutated (63.0%).Another study from MD Anderson (Cancer Discovery Project), shows TP53as the most mutated gene in OSCC patients (Figure3A), being R175H and R110L the most recurrent mutations (Figure 3B).